Augmentation Strategies for Treatment Resistant Major Depression: A Systematic Review and Network Meta-analysis

Overview

Journal J Affect Disord

Date 2022 Jan 5

PMID 34986373

Citations 45

Authors

Nicolas A Nunez

Boney Joseph

Mehak Pahwa

Rakesh Kumar

Manuel Gardea Resendez

Larry J Prokop

Marin Veldic

Ashok Seshadri

Joanna M Biernacka

Mark A Frye

Zhen Wang

Balwinder Singh

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the efficacy and discontinuation of augmentation agents in adult patients with treatment-resistant depression (TRD). We conducted a systematic review and network meta-analyses (NMA) to combine direct and indirect comparisons of augmentation agents.

Methods: We included randomized controlled trials comparing one active drug with another or with placebo following a treatment course up to 24 weeks. Nineteen agents were included: stimulants, atypical antipsychotics, thyroid hormones, antidepressants, and mood stabilizers. Data for response/remission and all-cause discontinuation rates were analyzed. We estimated effect-size by relative risk using pairwise and NMA with random-effects model.

Results: A total of 65 studies (N = 12,415) with 19 augmentation agents were included in the NMA. Our findings from the NMA for response rates, compared to placebo, were significant for: liothyronine, nortriptyline, aripiprazole, brexpiprazole, quetiapine, lithium, modafinil, olanzapine (fluoxetine), cariprazine, and lisdexamfetamine. For remission rates, compared to placebo, were significant for: thyroid hormone(T4), aripiprazole, brexpiprazole, risperidone, quetiapine, and olanzapine (fluoxetine). Compared to placebo, ziprasidone, mirtazapine, and cariprazine had statistically significant higher discontinuation rates. Overall, 24% studies were rated as having low risk of bias (RoB), 63% had moderate RoB and 13% had high RoB.

Limitations: Heterogeneity in TRD definitions, variable trial duration and methodological clinical design of older studies and small number of trials per comparisons.

Conclusions: This NMA suggests a superiority of the regulatory approved adjunctive atypical antipsychotics, thyroid hormones, dopamine compounds (modafinil and lisdexamfetamine) and lithium. Acceptability was lower with ziprasidone, mirtazapine, and cariprazine. Further research and head-to-head studies should be considered to strengthen the best available options for TRD.

Citing Articles

Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis.

Larsen A, Teobaldi G, Espinoza Jeraldo R, Falkai P, Cooper C BMJ Ment Health. 2025; 28(1).

PMID: 40032553 PMC: 11877238. DOI: 10.1136/bmjment-2024-301324.

Brain connectivity correlates of the impact of a digital intervention for individuals with subjective cognitive decline on depression and IL-18.

Catalogna M, Somerville Y, Saporta N, Nathansohn-Levi B, Shelly S, Edry L Sci Rep. 2025; 15(1):6863.

PMID: 40011544 PMC: 11865443. DOI: 10.1038/s41598-025-91457-3.

Increased Interleukin-6 Levels in Responders with Treatment-Resistant Depression After Bright Light Therapy.

Kosanovic Rajacic B, Sagud M, Begic D, Nikolac Perkovic M, Kozmar A, Rogic D Biomolecules. 2025; 15(2).

PMID: 40001598 PMC: 11852636. DOI: 10.3390/biom15020295.

Trends in research on novel antidepressant treatments.

Zelek-Molik A, Litwa E Front Pharmacol. 2025; 16:1544795.

PMID: 39931695 PMC: 11807967. DOI: 10.3389/fphar.2025.1544795.

Sex-modulated association between thyroid stimulating hormone and informant-perceived anxiety in non-depressed older adults: Prediction models and relevant cutoff value.

Hallab A Sci Rep. 2025; 15(1):2526.

PMID: 39833340 PMC: 11747398. DOI: 10.1038/s41598-025-86703-7.

References

Shelton R, Williamson D, Corya S, Sanger T, Van Campen L, Case M . Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005; 66(10):1289-97. DOI: 10.4088/jcp.v66n1012. View

Goss A, Kaser M, Costafreda S, Sahakian B, Fu C . Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013; 74(11):1101-7. DOI: 10.4088/JCP.13r08560. View

Shelton R, Papakostas G . Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008; 117(4):253-9. DOI: 10.1111/j.1600-0447.2007.01130.x. View

Thase M, Youakim J, Skuban A, Hobart M, Zhang P, McQuade R . Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015; 76(9):1232-40. DOI: 10.4088/JCP.14m09689. View

Madhoo M, Keefe R, Roth R, Sambunaris A, Wu J, Trivedi M . Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2013; 39(6):1388-98. PMC: 3988542. DOI: 10.1038/npp.2013.334. View

Corrigan M, Denahan A, Wright C, Ragual R, Evans D . Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000; 11(2):58-65. DOI: 10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Fava M, Thase M, DeBattista C . A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005; 66(1):85-93. DOI: 10.4088/jcp.v66n0112. View

Stein G, Bernadt M . Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993; 162:634-40. DOI: 10.1192/bjp.162.5.634. View

10.

Keitner G, Garlow S, Ryan C, Ninan P, Solomon D, Nemeroff C . A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res. 2008; 43(3):205-14. PMC: 3685867. DOI: 10.1016/j.jpsychires.2008.05.003. View

11.

Barbee J, Thompson T, Jamhour N, Stewart J, Conrad E, Reimherr F . A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry. 2011; 72(10):1405-12. DOI: 10.4088/JCP.09m05355gre. View

12.

McIntyre R, Filteau M, Martin L, Patry S, Carvalho A, Cha D . Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2013; 156:1-7. DOI: 10.1016/j.jad.2013.10.043. View

13.

Dunlop B, Crits-Christoph P, Evans D, Hirschowitz J, Solvason H, Rickels K . Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007; 27(6):614-9. DOI: 10.1097/jcp.0b013e31815abefb. View

14.

Kennedy S, Lam R, McIntyre R, Tourjman S, Bhat V, Blier P . Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016; 61(9):540-60. PMC: 4994790. DOI: 10.1177/0706743716659417. View

15.

Spielmans G, Berman M, Linardatos E, Rosenlicht N, Perry A, Tsai A . Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. Focus (Am Psychiatr Publ). 2020; 14(2):244-265. PMC: 6519642. DOI: 10.1176/appi.focus.140202. View

16.

McIntyre A, Gendron A, McIntyre A . Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2006; 24(7):487-94. DOI: 10.1002/da.20275. View

17.

Barbosa L, Berk M, Vorster M . A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003; 64(4):403-7. DOI: 10.4088/jcp.v64n0407. View

18.

Santos M, Rocha F, Hara C . Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Prim Care Companion J Clin Psychiatry. 2008; 10(3):187-90. PMC: 2446484. DOI: 10.4088/pcc.v10n0302. View

19.

DeBattista C, Doghramji K, Menza M, Rosenthal M, Fieve R . Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003; 64(9):1057-64. DOI: 10.4088/jcp.v64n0911. View

20.

Schindler F, Anghelescu I . Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol. 2007; 22(3):179-82. DOI: 10.1097/YIC.0b013e328014823d. View